Literature DB >> 8762097

PPADS and suramin as antagonists at cloned P2Y- and P2U-purinoceptors.

S J Charlton1, C A Brown, G A Weisman, J T Turner, L Erb, M R Boarder.   

Abstract

1. The effect of suramin and pyridoxalphosphate-6-azophenyl-2',4'-disulphonic acid (PPADS) on the stimulation of phospholipase C in 1321N1 cells transfected with the human P2U-purinoceptor (h-P2U-1321N1 cells) or with the turkey P2Y-purinoceptor (t-P2Y-1321N1 cells) was investigated. 2-Methylthioadenosine triphosphate (2MeSATP) was used as the agonist at t-P2Y-1321N1 cells and uridine triphosphate (UTP) at h-P2U-1321N1 cells. 2. Suramin caused a parallel shift to the right of the concentration-response curves for 2MeSATP in the t-P2Y-1321N1 cells, yielding a Schild plot with a slope of 1.16 +/- 0.08 and a pA2 value of 5.77 +/- 0.11. 3. Suramin also caused a shift to the right of concentration-response curves for UTP in the h-P2U-1321N1 cells, and on Schild plots gave a slope different from unity (1.57 +/- 0.19) and an apparent pA2 value of 4.32 +/- 0.13. Suramin was therefore a less potent antagonist at the P2U-purinoceptor than the P2Y-purinoceptor. 4. In the presence of the ectonucleotidase inhibitor, ARL 67156 (6-N,N-diethyl-beta,gamma-dibromomethylene-D-ATP) there was no significant difference in the EC50 or shapes of curves with either cell type, and no difference in pA2 values for suramin. 5. PPADS caused an increase in the EC50 for 2MeSATP in the t-P2Y-1321N1 cells. The Schild plot had a slope different from unity (0.55 +/- 0.15) and an X-intercept corresponding to an apparent pA2 of 5.98 +/- 0.65. 6. PPADS up to 30 microM had no effect on the concentration-response curve for UTP with the h-P2U-1321N1 cells. 7. In conclusion, suramin and PPADS show clear differences in their action at the 2 receptor types, in each case being substantially more effective as an antagonist at the P2Y-purinoceptor than at the P2U-purinoceptor. Ectonucleotidase breakdown had little influence on the nature of the responses at the two receptor types, or in their differential sensitivity to suramin.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8762097      PMCID: PMC1909747          DOI: 10.1111/j.1476-5381.1996.tb15457.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  37 in total

1.  PPADS, a novel functionally selective antagonist of P2 purinoceptor-mediated responses.

Authors:  G Lambrecht; T Friebe; U Grimm; U Windscheif; E Bungardt; C Hildebrandt; H G Bäumert; G Spatz-Kümbel; E Mutschler
Journal:  Eur J Pharmacol       Date:  1992-07-07       Impact factor: 4.432

2.  Suramin is a slowly-equilibrating but competitive antagonist at P2x-receptors in the rabbit isolated ear artery.

Authors:  P Leff; B E Wood; S E O'Connor
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

3.  Expression cloning of an ATP receptor from mouse neuroblastoma cells.

Authors:  K D Lustig; A K Shiau; A J Brake; D Julius
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

Review 4.  Is there a basis for distinguishing two types of P2-purinoceptor?

Authors:  G Burnstock; C Kennedy
Journal:  Gen Pharmacol       Date:  1985

Review 5.  Further subclassification of ATP receptors based on agonist studies.

Authors:  S E O'Connor; I A Dainty; P Leff
Journal:  Trends Pharmacol Sci       Date:  1991-04       Impact factor: 14.819

6.  The effects of some possible inhibitors of ectonucleotidases on the breakdown and pharmacological effects of ATP in the guinea-pig urinary bladder.

Authors:  S M Hourani; J A Chown
Journal:  Gen Pharmacol       Date:  1989

7.  Neuronal "nucleotide" receptor linked to phospholipase C and phospholipase D? Stimulation of PC12 cells by ATP analogues and UTP.

Authors:  R J Murrin; M R Boarder
Journal:  Mol Pharmacol       Date:  1992-03       Impact factor: 4.436

8.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

9.  The regulation of aortic endothelial cells by purines and pyrimidines involves co-existing P2y-purinoceptors and nucleotide receptors linked to phospholipase C.

Authors:  G F Wilkinson; J R Purkiss; M R Boarder
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

10.  Suramin antagonizes responses to P2-purinoceptor agonists and purinergic nerve stimulation in the guinea-pig urinary bladder and taenia coli.

Authors:  C H Hoyle; G E Knight; G Burnstock
Journal:  Br J Pharmacol       Date:  1990-03       Impact factor: 8.739

View more
  37 in total

1.  Extracellular ATP or ADP induce chemotaxis of cultured microglia through Gi/o-coupled P2Y receptors.

Authors:  S Honda; Y Sasaki; K Ohsawa; Y Imai; Y Nakamura; K Inoue; S Kohsaka
Journal:  J Neurosci       Date:  2001-03-15       Impact factor: 6.167

2.  P2Y purinoceptor activation mobilizes intracellular Ca2+ and induces a membrane current in rat intracardiac neurones.

Authors:  D M Liu; C Katnik; M Stafford; D J Adams
Journal:  J Physiol       Date:  2000-07-15       Impact factor: 5.182

3.  Nucleotide-mediated relaxation in guinea-pig aorta: selective inhibition by MRS2179.

Authors:  Robert A Kaiser; Iain L O Buxton
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

Review 4.  Molecular recognition in P2 receptors: ligand development aided by molecular modeling and mutagenesis.

Authors:  K A Jacobson; C Hoffmann; Y C Kim; E Camaioni; E Nandanan; S Y Jang; D P Guo; X D Ji; I von Kügelgen; S Moro; A U Ziganshin; A Rychkov; B F King; S G Brown; S S Wildman; G Burnstock; J L Boyer; A Mohanram; T K Harden
Journal:  Prog Brain Res       Date:  1999       Impact factor: 2.453

Review 5.  International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy.

Authors:  Maria P Abbracchio; Geoffrey Burnstock; Jean-Marie Boeynaems; Eric A Barnard; José L Boyer; Charles Kennedy; Gillian E Knight; Marta Fumagalli; Christian Gachet; Kenneth A Jacobson; Gary A Weisman
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

6.  Role of P2 purinergic receptors in synaptic transmission under normoxic and ischaemic conditions in the CA1 region of rat hippocampal slices.

Authors:  Elisabetta Coppi; Anna Maria Pugliese; Holger Stephan; Christa E Müller; Felicita Pedata
Journal:  Purinergic Signal       Date:  2007-01-03       Impact factor: 3.765

7.  Evidence for two different P2X-receptors mediating vasoconstriction of Ap5A and Ap6A in the isolated perfused rat kidney.

Authors:  M van der Giet; O Cinkilic; J Jankowski; M Tepel; W Zidek; H Schlüter
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

Review 8.  P2 receptor subtypes in the cardiovascular system.

Authors:  S P Kunapuli; J L Daniel
Journal:  Biochem J       Date:  1998-12-15       Impact factor: 3.857

Review 9.  Nucleotide receptors in the nervous system. An abundant component using diverse transduction mechanisms.

Authors:  E A Barnard; J Simon; T E Webb
Journal:  Mol Neurobiol       Date:  1997-10       Impact factor: 5.590

10.  High-Throughput HIV-Cell Fusion Assay for Discovery of Virus Entry Inhibitors.

Authors:  Mariana Marin; Yuhong Du; Charline Giroud; Jeong Hwa Kim; Min Qui; Haian Fu; Gregory B Melikyan
Journal:  Assay Drug Dev Technol       Date:  2015-04-14       Impact factor: 1.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.